Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial Article

sustainable development goals

SDG 03: Good Health and Well-being

publication date

January 23, 2023

webpage

Web of Science

published in

BRITISH JOURNAL OF DERMATOLOGY Journal

start page

22

end page

31

volume

188

issue

1